Cargando…

Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity

We seek to further addresss the questions posed by Moseson et al. regarding whether any residual crystal level, size, or characteristic is acceptable in an amorphous solid dispersion (ASD) such that its stability, enhanced dissolution, and increased bioavailability are not compromised. To address th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davis, Daniel A., Miller, Dave A., Santitewagun, Supawan, Zeitler, J. Axel, Su, Yongchao, Williams, Robert O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683684/ https://www.ncbi.nlm.nih.gov/pubmed/34977559 http://dx.doi.org/10.1016/j.ijpx.2021.100092

Ejemplares similares

Engineering of Nanofibrous Amorphous and Crystalline Solid Dispersions for Oral Drug Delivery
por: Modica de Mohac, Laura, et al.
Publicado: (2018)

Utilizing Drug Amorphous Solid Dispersions for the Preparation of Dronedarone per os Formulations
por: Kapourani, Afroditi, et al.
Publicado: (2023)

Amorphous Solid Dispersion as Drug Delivery Vehicles in Cancer
por: Budiman, Arif, et al.
Publicado: (2023)

Formulation Characterization and Pharmacokinetic Evaluation of Amorphous Solid Dispersions of Dasatinib
por: Dharani, Sathish, et al.
Publicado: (2022)

Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of Drugs: Composition, Preparation, Characterization and Formulations for Oral Delivery
por: Karagianni, Anna, et al.
Publicado: (2018)

Role of Microstructure in Drug Release from Chitosan Amorphous Solid Dispersions
por: Lucio, David, et al.
Publicado: (2022)

Molecular Simulation and Statistical Learning Methods toward Predicting Drug–Polymer Amorphous Solid Dispersion Miscibility, Stability, and Formulation Design
por: Walden, Daniel M., et al.
Publicado: (2021)

Tunneling systems in amorphous and crystalline solids
por: Esquinazi, Pablo
Publicado: (1998)

Homogenization of Amorphous Solid Dispersions Prepared by Electrospinning in Low-Dose Tablet Formulation
por: Fülöp, Gergő, et al.
Publicado: (2018)

Myth or Truth: The Glass Forming Ability Class III Drugs Will Always Form Single-Phase Homogenous Amorphous Solid Dispersion Formulations
por: Panini, Piyush, et al.
Publicado: (2019)

Impact of Gastric pH Variations on the Release of Amorphous Solid Dispersion Formulations Containing a Weakly Basic Drug and Enteric Polymers
por: Nguyen, Hanh Thuy, et al.
Publicado: (2023)

Exploring the Role of Surfactants in Enhancing Drug Release from Amorphous Solid Dispersions at Higher Drug Loadings
por: Saboo, Sugandha, et al.
Publicado: (2021)

Drug-Rich Phases Induced by Amorphous Solid Dispersion: Arbitrary or Intentional Goal in Oral Drug Delivery?
por: Qian, Kaijie, et al.
Publicado: (2021)

The Need for Restructuring the Disordered Science of Amorphous Drug Formulations
por: Edueng, Khadijah, et al.
Publicado: (2017)

FORMULATION OF FUROSEMIDE SOLID DISPERSION WITH MICRO CRYSTALLINE CELLULOSE FOR ACHIEVE RAPID DISSOLUTION
por: Patel, Rajanikant C., et al.
Publicado: (2010)

Superiority of Mesoporous Silica-Based Amorphous Formulations over Spray-Dried Solid Dispersions
por: Zhang, Hongwei, et al.
Publicado: (2022)

Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization
por: Tambe, Srushti, et al.
Publicado: (2022)

Fed- and Fasted-State Performance of Pretomanid Amorphous Solid Dispersions Formulated with an Enteric Polymer
por: Nguyen, Hanh Thuy, et al.
Publicado: (2023)

Combining drug salt formation with amorphous solid dispersions – a double edged sword
por: Hiew, Tze Ning, et al.
Publicado: (2022)

Effect of Drug–Polymer Interaction in Amorphous Solid Dispersion on the Physical Stability and Dissolution of Drugs: The Case of Alpha-Mangostin
por: Budiman, Arif, et al.
Publicado: (2023)

Benchmarking the Solubility Enhancement and Storage Stability of Amorphous Drug–Polyelectrolyte Nanoplex against Co-Amorphous Formulation of the Same Drug
por: Lim, Li Ming, et al.
Publicado: (2022)

Determination of Stable Co-Amorphous Drug–Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures
por: Kissi, Eric Ofosu, et al.
Publicado: (2019)

Continuous Formulation Approaches of Amorphous Solid Dispersions: Significance of Powder Flow Properties and Feeding Performance
por: Szabó, Edina, et al.
Publicado: (2019)

Thermal Stability of Amorphous Solid Dispersions
por: Jelić, Dijana
Publicado: (2021)

Drug crystal growth in ternary amorphous solid dispersions: Effect of surfactants and polymeric matrix-carriers
por: Kapourani, Afroditi, et al.
Publicado: (2021)

Crystallization and Phase Changes in Paracetamol from the Amorphous Solid to the Liquid Phase
por: Sibik, Juraj, et al.
Publicado: (2014)

Formulation of Orally Disintegrating Films as an Amorphous Solid Solution of a Poorly Water-Soluble Drug
por: Panraksa, Pattaraporn, et al.
Publicado: (2020)

A Novel Rheological Method to Assess Drug-Polymer Interactions Regarding Miscibility and Crystallization of Drug in Amorphous Solid Dispersions for Oral Drug Delivery
por: Tsakiridou, Georgia, et al.
Publicado: (2019)

Unravelling the Miscibility of Poly(2-oxazoline)s: A Novel Polymer Class for the Formulation of Amorphous Solid Dispersions
por: Everaerts, Melissa, et al.
Publicado: (2020)

A Hot-Melt Extrusion Risk Assessment Classification System for Amorphous Solid Dispersion Formulation Development
por: Kyeremateng, Samuel O., et al.
Publicado: (2022)

Amorphous chalcogels with local crystallinity
por: Yang, Lijun, et al.
Publicado: (2022)

Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
por: Ruponen, Marika, et al.
Publicado: (2021)

The balance of crystalline and amorphous regions in the fibroin structure underpins the tensile strength of bagworm silk
por: Kono, Nobuaki, et al.
Publicado: (2021)

Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies
por: Liu, Jingwen, et al.
Publicado: (2021)

Influence of Drug Load on the Printability and Solid-State Properties of 3D-Printed Naproxen-Based Amorphous Solid Dispersion
por: Kissi, Eric Ofosu, et al.
Publicado: (2021)

Enhanced Supersaturation via Fusion-Assisted Amorphization during FDM 3D Printing of Crystalline Poorly Soluble Drug Loaded Filaments
por: Buyukgoz, Guluzar Gorkem, et al.
Publicado: (2021)

Insights into the Control of Drug Release from Complex Immediate Release Formulations
por: Dong, Runqiao, et al.
Publicado: (2021)

Preparation of biocompatible heat-labile enterotoxin subunit B-bovine serum albumin nanoparticles for improving tumor-targeted drug delivery via heat-labile enterotoxin subunit B mediation
por: Zhao, Liang, et al.
Publicado: (2014)

Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools
por: Triboandas, Hetvi, et al.
Publicado: (2022)

Improved Dissolution and Pharmacokinetics of Abiraterone through KinetiSol(®) Enabled Amorphous Solid Dispersions
por: Gala, Urvi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gplh5pa9dl97t7ehc6osge1dvd